Prezzo Variazione Volume P/E
20.99 +0.52 €
7687 0.00


Altri utenti che hanno investito

Transations in last week
Sell :



This RSS feed URL is deprecated


Zacks: Rubius Therapeutics Inc (RUBY) Given $33.75 Average Target Price by Analysts - Baseball Daily News

Rubius Therapeutics Inc (NASDAQ:RUBY) has received an average broker rating score of 1.13 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy ...altro » Leggi

Rubius Therapeutics, Inc. (RUBY) stock locked down along -4.39% to its 50- SMA - Nasdaq Place (press release)

Rubius Therapeutics, Inc. (RUBY) stock price moved Upswing along with the volume 0.11 million shares in Tuesday session. Shares are clocking price at $21.90 with change of 1.34%. Current trade price levels places RUBY's stock about -33.66% away from ... Leggi

Rubius Therapeutics, Inc. (RUBY) stock price is -4.39% lower to 200- SMA - Nasdaq Place (press release)

Current trade price levels places RUBY's stock about -33.66% away from the 52-week high and closed 11.34% away from the 52-week low. The total dollar value of all 71.78 million outstanding shares is 1.57 billion. The company's 3-months average volume ... Leggi

Rubius Therapeutics (RUBY): Keep Your Eyes on Healthcare Stock: - Stock Digest (press release)

Rubius Therapeutics (RUBY):. Every trading day indicate diverse behavior and trends about Rubius Therapeutics (RUBY) stock. Now we observed the different factors that seen on close of Wednesday session. At the end of the day, it's only a stock's ... Leggi

Shareholders Should Check If Insiders Own Shares In Rubius Therapeutics Inc (NASDAQ:RUBY) - Simply Wall St

Institutional investors transact in large blocks which can influence the momentum of stock prices, at least in the short-term, especially when there is a low level of public shares available on the market to trade. With an institutional ownership of 5 ... Leggi

Zacks: Analysts Expect Rubius Therapeutics Inc (RUBY) to Post -$0.36 Earnings Per Share - Fairfield Current

Equities research analysts predict that Rubius Therapeutics Inc (NASDAQ:RUBY) will announce ($0.36) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have ... Read More: Average Daily Trade Volume Explained · Get a free ...altro » Leggi

Stock-research Ratings: CSG Systems International, Inc. (CSGS), Rubius Therapeutics, Inc. (RUBY) - Analyst Journal

CSG Systems International, Inc. (NASDAQ:CSGS) tinted gains of +1.35% (+0.55 points) to US$41.31. The volume of 0.17 Million shares climbed down over an trading activity of 169.51 Million shares. EPS ratio determined by looking at last 12 month figures ...altro » Leggi

Rubius Therapeutics sees greater net loss in 2Q as its ramps up its cell therapy investments - Proactive Investors USA & Canada

Rubius Therapeutics Inc (NASDAQ:RUBY) announced its second-quarter results following its initial public offering in July. The biotech reported a ... of US$95mln through 2020. Shares of Rubius Therapeutics were flat at US$25.01 in Friday pre-market trading.altro » Leggi

Rubius Therapeutics (RUBY) Given Daily News Impact Score of 0.11 - Baseball Daily Digest

Rubius Therapeutics earned a news sentiment score of 0.11 on Accern's scale. Accern also assigned news coverage about the company an impact score of 45.5402218910935 out of 100, indicating that recent press coverage is somewhat unlikely to have an ... Leggi

Biotech IPOs Are Booming … but for How Long? - BioSpace (press release) (blog)

Companies that sold stock for the first time in 2018 include Translate Bio Inc., which is using messenger RNA to develop drugs for rare diseases such as cystic fibrosis, and Neon Therapeutics Inc., which describes itself as a platform for developing ... Leggi